MX2018016118A - Carotenoides microbianos que afectan la composicion de la microbiota intestinal. - Google Patents

Carotenoides microbianos que afectan la composicion de la microbiota intestinal.

Info

Publication number
MX2018016118A
MX2018016118A MX2018016118A MX2018016118A MX2018016118A MX 2018016118 A MX2018016118 A MX 2018016118A MX 2018016118 A MX2018016118 A MX 2018016118A MX 2018016118 A MX2018016118 A MX 2018016118A MX 2018016118 A MX2018016118 A MX 2018016118A
Authority
MX
Mexico
Prior art keywords
microbial
composition
carotenoids
compound
apo
Prior art date
Application number
MX2018016118A
Other languages
English (en)
Inventor
Possemiers Sam
Marzorati Massimo
Bolca Selin
Duysburgh Cindy
Pinheiro Iris
Van Den Abbeele Pieter
Original Assignee
Prodigest Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prodigest Bvba filed Critical Prodigest Bvba
Publication of MX2018016118A publication Critical patent/MX2018016118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere al uso de carotenoides, en particular un compuesto de carotenoides microbiano de la fórmula I, tal como metilglicosilapo- 8'-licopenoato o glicosil-apo-8'-licopeno, para restaurar y/o mantener la composición de la microbiota intestinal benéfica para la salud en un sujeto. La invención proporciona además el uso de dicho compuesto en el tratamiento de trastornos asociados con la integridad alterada de la barrera intestinal, tal como, por ejemplo, el síndrome del intestino irritable. Además, se describe un compuesto o composición que comprende un compuesto de carotenoides microbianos para su uso en la prevención y/o tratamiento de trastornos asociados con la integridad alterada de la barrera intestinal.
MX2018016118A 2016-06-22 2017-06-22 Carotenoides microbianos que afectan la composicion de la microbiota intestinal. MX2018016118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16175832 2016-06-22
PCT/EP2017/065348 WO2017220708A1 (en) 2016-06-22 2017-06-22 Microbial carotenoids affecting gut microbial composition

Publications (1)

Publication Number Publication Date
MX2018016118A true MX2018016118A (es) 2019-07-08

Family

ID=56203217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016118A MX2018016118A (es) 2016-06-22 2017-06-22 Carotenoides microbianos que afectan la composicion de la microbiota intestinal.

Country Status (12)

Country Link
US (1) US11324717B2 (es)
EP (1) EP3474862A1 (es)
JP (1) JP6966543B2 (es)
KR (1) KR102413408B1 (es)
CN (1) CN109641006B (es)
AU (1) AU2017281589B2 (es)
BR (1) BR112018076485A8 (es)
CA (1) CA3028031C (es)
IL (1) IL263683B (es)
MX (1) MX2018016118A (es)
RU (1) RU2759600C2 (es)
WO (1) WO2017220708A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890808A4 (en) 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
AU2015339290B8 (en) 2014-10-30 2021-08-26 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3579924A4 (en) * 2017-02-07 2020-12-23 California Institute of Technology MODULATION OF THE INTESTINAL FLORA IN HUNTINGTON'S MORBUS AND RETT'S SYNDROME
CN110283754B (zh) * 2019-07-11 2021-02-02 中国科学院北京基因组研究所 用于类风湿关节炎炎症状态评估及预后评价的肠道微生物菌群
KR102369996B1 (ko) * 2020-04-21 2022-03-02 박선민 대사성 질환과 안질환의 예방 및 건강 유지를 위한 장내 미생물 검사 기반 맞춤형 프리바이오틱스 또는 프로바이오틱스 정보 제공방법
CN115606802A (zh) * 2022-10-21 2023-01-17 中国农业大学 番茄红素在制备修复肠屏障损伤的产品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
GB0524873D0 (en) * 2005-12-06 2006-01-11 New Royal Holloway & Bedford Bacterial production of carotenoids
GB201013041D0 (en) * 2010-08-03 2010-09-15 Royal Holloway & New Bedford College Carotenoids

Also Published As

Publication number Publication date
BR112018076485A8 (pt) 2022-12-06
IL263683A (en) 2019-01-31
RU2019101481A (ru) 2020-07-22
IL263683B (en) 2022-04-01
EP3474862A1 (en) 2019-05-01
US20190209516A1 (en) 2019-07-11
CA3028031A1 (en) 2017-12-28
KR20190039687A (ko) 2019-04-15
JP6966543B2 (ja) 2021-11-17
JP2019524877A (ja) 2019-09-05
CN109641006A (zh) 2019-04-16
KR102413408B1 (ko) 2022-06-27
CN109641006B (zh) 2022-07-01
CA3028031C (en) 2023-02-28
WO2017220708A1 (en) 2017-12-28
US11324717B2 (en) 2022-05-10
RU2759600C2 (ru) 2021-11-16
AU2017281589B2 (en) 2023-03-23
BR112018076485A2 (pt) 2019-04-09
AU2017281589A1 (en) 2019-01-31
RU2019101481A3 (es) 2020-10-16

Similar Documents

Publication Publication Date Title
MX2018016118A (es) Carotenoides microbianos que afectan la composicion de la microbiota intestinal.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2018012174A (es) Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
WO2018134685A3 (en) Compounds
WO2015003816A3 (en) Cystobactamides
MX2014015197A (es) Tratamiento y prevencion de la enfermedad cardiovascular y trombosis.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3833346A4 (en) COMPOSITIONS FOR THE PREVENTION AND REVERSAL OF THE EFFECTS OF OPIATES AND OPIOIDS, AND METHODS OF USE THEREOF
WO2017147130A3 (en) Direct fed microbial for prevention of shrimp disease
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
ZA202002093B (en) Antibacterial compounds
MY191930A (en) Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
JOP20180029A1 (ar) مركب حلقي غير متجانس
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
BR112017013845A2 (pt) derivados de glucagon
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2021015961A (es) Moleculas novedosas.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.